BBTV

About Us

all episodes

The Tel-Aviv Stock Exchange (TASE) for Biomed Companies and Investors

TASE

How does the Tel-Aviv Stock Exchange (TASE) compare to the NASDAQ, AMEX, and other U.S. exchanges? What is the rationale for U.S. biomed investors to look at TASE-listed companies?

“In the Absence of a Cure, Quality of Life is Key” Alzheimer’s Foundation of America

alz90x90

Eric J. Hall, CEO, and Bert Brodsky, Chairman of the Alzheimer’s Foundation of America, discuss hope for a cure, participation in clinical trials, diagnostics, and the socio-economic impact of the disease.

AMRS – Amyris CEO John G. Melo Interviewed by Boonsri Dickinson

amyris 90x90
  1. Reprogramming yeast to make high value carbons for use in consumer goods and energy markets
  2. Amyris’ IP portfolio and Sanofi’s no-fee license for malaria
  3. A platform and a product that will compete with Dupont and BSF while being managed like a jazz band
  4. Bolt-on facilities allow focused effort and capital on fermentation, not agriculture
  5. Business model : low cost, large scale, long demand
  6. Near term milestones and 5-10 year vision

An Interview with Steve Burrill

burrill-6-90
  1. Adapting to Change, an Interview with Steve Burrill
  2. No Real Healthcare Reform, Only Insurance Reform
  3. Financing Biotech in 2010
  4. From Personalized Medicine to Preemptive Medicine
  5. Stem Cells and Other Promising New Technologies
  6. FAST Word Association Game, with Steve Burrill

Fred Frank and Dennis Purcell Comment on New Year

  1. 2009 in Review, the M&A and Venture Perspectives
  2. 2010, Where Do We Go From Here?
  3. FAST Word Association Game, with Fred Frank and Dennis Purcell

An Official NASDAQ Perspective on Biotech, with Bob McCooey

  1. Biotech Markets in 2009
  2. Expectations for Biotech in 2010
  3. Helping Smaller Biotech Companies Stay Listed

Osiris CEO on the Applications of Mesenchymal Stem Cells

Randy Mills discusses the therapeutical and commercial applications of mesenchymal stem cells with Bill Kridel.

Visionaries: Stelios Papadopoulos

1. Financing, Productivity, and the Cost of Innovation.
2. Biotech in 20 Years, Fundamental Science, Personalized Medicine, and Energy.

Vaccine and Antibody Production from Stem Cells, Vivalis

Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production. Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, ...

I-Stem, Peschanski’s Stem Cell Technology Platform

  1. Standardizing Ways to Create New Treatments for Under-served Disease Markets, with Stem Cell Technology
  2. Is Europe attractive for stem cell research? Which countries are the most advanced and have the most favorable legislation?
  3. Stem Cell Research Financing, Products, Business Models, and Regulatory Concerns
  4. Will Adult Stem Cells Resolve Our Moral Quandaries? Do They Offer The Same Benefits As Embryonic Stem Cells?

  • Best of the Web

    • Alzheimer's Disease
    • Antibiotic Resistance
    • Cancer Immunotherapy
    • Cell Therapy
    • Hepatitis C
    • LOL
    • Stem Cells
    • - View All -

  • Series

    • The Stem Cell Review
    • Cancer Immunotherapy

  • Shows

    • Biotech in the Money
    • Wall Street On BBTV
    • Science Breakthrough
    • The Jan Buck Show
    • Special Interview
    • Report on Location

  • Corporate Videos

    • 60sec Pitches
    • Investor Presentations
    • Panorama

  • Store

    • Series Sponsorship
    • Corp. Communications
    • DVDs
  • ABOUT BIOBUSINESS.TV
  • BioBusiness.TV is the first independent Internet TV Network for biotechnology professionals. We create and syndicate video-based industry focused shows and series that range from scientific breakthroughs, to equity analyst insights, as well as C-level executive and investor interviews on strategy, management, policy, marketing, science and more. We strive to enhance the quality and accessibility of industry video programming, and to deliver information biotechnology professionals can rely on to make sound and informed decisions.
  • PARTNERING WITH BIOBUSINESS.TV
  • If you’ve got great video programs and a growing audience, let BioBusiness.TV help you take it to the next level through our Partner Program. You can reach out to us through our ‘contact us’ page.
  • DISCLAIMER
  • Viewers should verify all claims and do their own due diligence before investing in any securities mentioned on BioBusiness.TV.
  • COPYRIGHT © 2011 BIO BUSINESS TV, INC. All Rights Reserved